These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. p53 and Ki-ras gene mutations in epithelial ovarian neoplasms. Teneriello MG, Ebina M, Linnoila RI, Henry M, Nash JD, Park RC, Birrer MJ. Cancer Res; 1993 Jul 01; 53(13):3103-8. PubMed ID: 8319218 [Abstract] [Full Text] [Related]
8. Mutation of the Ki-ras protooncogene in human endometrial hyperplasia and carcinoma. Sasaki H, Nishii H, Takahashi H, Tada A, Furusato M, Terashima Y, Siegal GP, Parker SL, Kohler MF, Berchuck A. Cancer Res; 1993 Apr 15; 53(8):1906-10. PubMed ID: 8467512 [Abstract] [Full Text] [Related]
11. Mutations in the Kirsten-ras oncogene are common but lack correlation with prognosis and tumor stage in human pancreatic carcinoma. Motojima K, Urano T, Nagata Y, Shiku H, Tsunoda T, Kanematsu T. Am J Gastroenterol; 1991 Dec 15; 86(12):1784-8. PubMed ID: 1962623 [Abstract] [Full Text] [Related]
12. KRAS and BRAF mutations in ovarian tumors: a comprehensive study of invasive carcinomas, borderline tumors and extraovarian implants. Mayr D, Hirschmann A, Löhrs U, Diebold J. Gynecol Oncol; 2006 Dec 15; 103(3):883-7. PubMed ID: 16806438 [Abstract] [Full Text] [Related]
13. p53, Ki-ras, and DNA ploidy in human pancreatic ductal adenocarcinomas. Weyrer K, Feichtinger H, Haun M, Weiss G, Ofner D, Weger AR, Umlauft F, Grünewald K. Lab Invest; 1996 Jan 15; 74(1):279-89. PubMed ID: 8569192 [Abstract] [Full Text] [Related]
16. Studies on ras oncogene activation in endometrial carcinoma. Fujimoto I, Shimizu Y, Hirai Y, Chen JT, Teshima H, Hasumi K, Masubuchi K, Takahashi M. Gynecol Oncol; 1993 Feb 15; 48(2):196-202. PubMed ID: 8428691 [Abstract] [Full Text] [Related]
17. K-ras oncogene activation in adenocarcinoma of the human pancreas. A study of 82 carcinomas using a combination of mutant-enriched polymerase chain reaction analysis and allele-specific oligonucleotide hybridization. Hruban RH, van Mansfeld AD, Offerhaus GJ, van Weering DH, Allison DC, Goodman SN, Kensler TW, Bose KK, Cameron JL, Bos JL. Am J Pathol; 1993 Aug 15; 143(2):545-54. PubMed ID: 8342602 [Abstract] [Full Text] [Related]
18. The frequency of p53, K-ras mutations, and microsatellite instability differs in uterine endometrioid and serous carcinoma: evidence of distinct molecular genetic pathways. Lax SF, Kendall B, Tashiro H, Slebos RJ, Hedrick L. Cancer; 2000 Feb 15; 88(4):814-24. PubMed ID: 10679651 [Abstract] [Full Text] [Related]
19. Molecular evidence that most but not all carcinosarcomas of the uterus are combination tumors. Wada H, Enomoto T, Fujita M, Yoshino K, Nakashima R, Kurachi H, Haba T, Wakasa K, Shroyer KR, Tsujimoto M, Hongyo T, Nomura T, Murata Y. Cancer Res; 1997 Dec 01; 57(23):5379-85. PubMed ID: 9393763 [Abstract] [Full Text] [Related]
20. K-ras point mutations in endometrial carcinoma: effect on outcome is dependent on age of patient. Ito K, Watanabe K, Nasim S, Sasano H, Sato S, Yajima A, Silverberg SG, Garrett CT. Gynecol Oncol; 1996 Nov 01; 63(2):238-46. PubMed ID: 8910634 [Abstract] [Full Text] [Related] Page: [Next] [New Search]